full issue - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 5 (3) 1251-1272 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online)
1267
certain antihypertensive agents.
Hypertension, 2: 372-382.
12. Douglas, S.A., Dhanak, D. and Johns, D.G.
(2004). From ‘gills to pills’: urotensin-II
as a regulator of mammalian cardiorenal
function. Trends Pharmacol Sci, 25: 76-85.
13. Johnston, C.I., Hodsman, P.G., Kohzuki,
M., Casley, D.J., Fabris, B. and Phillips,
P.A. (1989). Interaction between atrial
natriuretic peptide and the renin angiotensin
aldosterone system. Endogenous
antagonists. Am J Med, 87: 24S-28S.
14. Balsamo, A., Calderone, V. and Rapposelli,
S. (2008). New emerging prospects in the
pharmacotherapy of hypertension.
Cardiovascular & Hematological Agents in
Medicinal Chemistry, 6: 1-19.
15. Masaki, T. (2000). The endothelin family:
an overview. Journal of Cardiovascular
Pharmacology, 35: S3-S5.
16. Hunley, T.E. and Kon, V. (2001). Update
on endothelins – biology and clinical
implications. Pediatr Nephrol, 16: 752–762.
17. Ortega, A. and De Artiñano, A. (1997).
Highlights on endothelins: a review.
Pharmacological Research, 36: 339-351.
18. Yanagisawa, M., Kurihawa, H., Kimura, S.,
Tomobe, Y., Kobayashi, M., Mitsui, Y.,
Yazaki, Y., Goto, K.and Masaki, T. (1988).
A novel potent vasoconstrictor peptide
produced by vascular endothelial cells.
Nature, 332: 411-415.
19. Takigawa, M., Sakurai, T., Kasuya, Y., Abe,
Y., Masaki, T. and Goto, K. (1995).
Molecular identification of guaninenucleotide-binding
regulatory proteins
which couple to endothelin receptors. Eur
J Biochem., 228: 102-108.
20. Goldie, R.G. (1999). Endothelins in health
and disease: an overview. Clinical and
Experimental Pharmacology and
Physiology, 26: 145-148.
21. Orry, A.J. and Wallace, B.A. (2000).
Modeling and docking the endothelin G-
protein-coupled receptor. Biophysical
Journal, 79: 3083-3094.
22. Lüscher, T.F. and Barton, M. (2000).
Endothelins and endothelin receptor
antagonists. Therapeutic considerations for
a novel class of cardiovascular drug.
Circulation, 102: 2434-2440.
23. Böhm, F. and Pernow, J. (2007). The
importance of endothelin-1 for vascular
dysfunction in cardiovascular disease.
Cardiovasc Res., 76: 8-18
24. DeNucci, G., Thomas, R., D’Orleans-Juste,
P., Antunes, E., Walder, C. and Warner, T.D.
(1988). Pressor effects of circulating
endothelin are limited by its removal in the
pulmonary circulation and by the release
of prostacyclin and endothelium derived
relaxing factor. Proc Natl Acad Sci USA,
85: 9797-9800.
25. Goto, K. (1999). History of endothelin. In:
Pulmonary actions of the endothelins.
Goldie, R.G., Hay, D.W., editors.
Kirkhäuser Verlag Basel, Switzerland, pp
1-20
26. Pullamsetti, S.S. and Schermuly, R.T.
(2009). Endothelin receptor antagonists in
preclinical models of pulmonary
hypertension. European Journal of Clinical
Investigation, 39: 3-13.
27. Zolk, O., Quattek, J., Sitzler, G., Schrader,
T., Nickening, G., Schnabel, P., Shimada,
K., Takahashi, M. and Bohm, M. (1999).
Expression of endothelin-1, endothelin-
Catherina Caballero-George